EZH2 and plasma cell myeloma: Considering this, and the fact that UNC1999, as well as other novel EZH2 inhibitors, are available for use in vivo [35, 55], it remains to be evaluated if EZH2 will constitute a novel druggable target with potent anti-myeloma effect in relevant murine models of MM.